Filing Overview
The supplied Form 10-Q is for Neuralstem, Inc., not Palisade Bio, Inc. It covers the quarterly and six-month periods ended June 30, 2014, with comparative periods ended June 30, 2013. Neuralstem develops human neuronal stem-cell therapies and small-molecule compounds; its principal programs were NSI-566 and NSI-189.
Financial Performance and Position
| Metric | Three Months Ended June 30, 2014 | Six Months Ended June 30, 2014 |
|---|---|---|
| Revenue | $5,000 | $9,167 |
| Operating expenses | $3.52 million | $8.70 million |
| Operating loss | $3.51 million | $8.69 million |
| Net loss | $6.75 million | $12.67 million |
| Loss per share | $0.08 | $0.15 |
- Six-month research and development expense was $3.52 million, down 4% year over year.
- Six-month general and administrative expense was $5.00 million, up 102%, primarily because of approximately $1.88 million of additional non-cash stock compensation and higher legal and professional fees.
- Six-month other expense was $3.98 million, including $3.11 million of warrant-modification expense, $830,000 of interest expense and $334,000 from changes in warrant liability fair value, partially offset by $250,000 of legal-settlement income.
- Cash used in operating activities was $5.12 million, compared with $5.87 million in the prior-year period.
- Cash used in investing activities was $15.39 million, principally reflecting the purchase of $15.00 million of short-term investments.
- Cash provided by financing activities was $18.90 million, including approximately $18.63 million of net proceeds from a January 2014 registered direct offering.
- At June 30, 2014, cash and cash equivalents were $15.23 million and short-term investments were $15.00 million. Total assets were $32.63 million and stockholders’ equity was $24.03 million.
- Debt consisted of approximately $6.6 million of aggregate principal outstanding, with approximately $300,000 of monthly principal and interest payments and substantially all assets, including intellectual property, pledged as collateral.
- Working capital surplus was approximately $25.85 million. Accumulated deficit was $141.10 million.
Material Changes Versus the Prior Comparable Period
- Six-month revenue declined to $9,000 from $105,000 because 2013 included an upfront licensing fee; 2014 revenue consisted of ongoing licensing fees only. No product sales were reported.
- Six-month net loss increased to $12.67 million from $9.84 million, despite lower research and development spending, primarily due to higher general and administrative expense and warrant-related charges.
- Weighted-average shares outstanding increased to 86.5 million from 69.6 million, reflecting equity offerings and warrant and option exercises.
- Cash and cash equivalents declined by $1.61 million from December 31, 2013, while short-term investments increased to $15.00 million from zero.
- Warrants underlying the derivative liability were exercised during the first quarter, leaving no derivative instruments recorded at June 30, 2014.
- Shareholders approved an increase of 150 million in authorized common shares, bringing the authorization to 300 million shares.
Outlook, Risks, and Unusual Items
- Management stated that available cash and expected income were expected to fund current activities through at least June 30, 2015, but not the full range of required clinical testing and development.
- The company expected continuing operating losses and stated that it would need significant additional financing. Effective shelf registrations and an at-the-market agreement provided potential financing capacity, but future funding was not assured.
- NSI-566 ALS Phase II transplantations were complete, with a six-month observation and data-collection period underway. A chronic spinal cord injury Phase I trial was expected to begin in the third quarter of 2014.
- The company expected to file a Phase II application for NSI-189 in major depressive disorder in the third or fourth quarter of 2014, with a trial potentially commencing near the end of the first quarter of 2015.
- Management expected research and development spending to increase as additional Phase II trials and other clinical programs progressed.
- Key risks include clinical-trial failure, regulatory delays or rejection, reliance on third-party manufacturers and clinical-service providers, intellectual-property disputes, limited commercialization experience, substantial debt service, possible dilution from future equity issuance and the need for additional capital.
- Ongoing litigation with StemCells, Inc. involved patent validity, infringement, standing and related claims. A bench trial on standing was scheduled to begin December 9, 2014; the ultimate outcome was uncertain.
- The $3.11 million warrant-modification charge and approximately $2.0 million of performance-related stock compensation were material non-cash or largely non-operating items affecting reported results.
- Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is Neuralstem, Inc., whereas the request identifies Palisade Bio, Inc.
- Verify cash runway assumptions against the company’s approximately $5.1 million six-month operating cash burn, debt payments and expected clinical-development spending.
- Review the terms, covenants, collateral and maturity schedule of the approximately $6.6 million debt facility.
- Assess potential dilution from the 300 million authorized common shares and approximately 44.2 million shares reserved for equity awards and outstanding instruments.
- Track clinical-trial enrollment, safety, efficacy and regulatory milestones for NSI-566 and NSI-189 rather than relying on early-stage or preliminary results.
- Monitor the StemCells litigation and any effects on patent rights, costs or commercialization plans.
- Reconcile reported net losses with non-cash warrant-modification, stock-compensation and derivative-fair-value charges.